Biotech

All Articles

Amgen documents first phase 3 gain for $400M chronic eczema medication

.Amgen has shared (PDF) the first stage 3 information on its own $400 thousand dermatitis medicine, ...

Biogen, UCB document phase 3 lupus win after falling short earlier test

.Biogen and UCB's depend advancing right into period 3 astride a broken study aims to have actually ...

Aptadir wishes brand-new RNA inhibitors can easily turn around difficult cancers

.Italian biotech Aptadir Rehabs has actually released along with the promise that its own pipe of pr...

Wave surfs DMD success to regulators' doors, sending stock up

.Wave Life Sciences has met its objective in a Duchenne muscle dystrophy (DMD) research study, placi...

Sanofi picks brand-new CSO from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is coming back to the pharma crease, occu...

Achilles drips tissue treatment program, prepares for discharges after missing 'business feasibility' objectives

.Achilles Rehabs has actually torn up its own tactic. The British biotech is stopping work on its cl...

Aligos trumpets phase 2 MASH gain, slashing liver excess fat as much as 46%

.Aligos Therapies is actually declaring a midstage gain in metabolic-dysfunction affiliated steatohe...

Basilea ratings $268M BARDA funding for antifungals, prescription antibiotics

.Basilea Pharmaceutica's job building brand new antifungals has actually received a notable increase...

Capricor sells Europe liberties to late-stage DMD treatment for $35M

.Having actually scooped up the united state rights to Capricor Rehabs' late-stage Duchenne muscle d...

FDA fragments adcomm for Applied's unusual disease medicine

.After dismissing the selection meeting for Applied Therapies' metabolic problem medication govorest...